Xeris delivers therapies for serious unmet medical needs by combining proprietary formulation technologies with deep clinical and commercial expertise - making informed decisions at every stage to ensure our work makes a meaningful difference in patients' lives.
Marketed Products
Development Stage | |
|---|---|
| Product/Candidate | Phase 1 Phase 2 Phase 3 Marketed |
Phase 1 Phase 2 Phase 3 Marketed | |
Phase 1 Phase 2 Phase 3 Marketed | |
Phase 1 Phase 2 Phase 3 Marketed |
Pipeline
We innovate, develop, and commercialize technologies that help patients live better lives:
- Through our own development and commercialization
- By helping partners improve patient administration and drug stability by licensing our proprietary formulation technologies
| The compound listed below is an investigational agent, and not FDA approved | Development Stage | ||
|---|---|---|---|
| Product/Candidate | Therapeutic Area | Phase 1 Phase 2 Phase 3 Marketed | |
XP-8121 (subcutaneous levothyroxine sodium) | Phase 1 Phase 2 Expect to initiate Phase 3 trial during 2H’26 Phase 3 Marketed |
| |
Xeris is growing our portfolio of strategic collaborations. To learn more about our robust partnership program and discuss collaboration opportunities, please contact us.
Proprietary Technology Platforms
Xeris’s nonaqueous proprietary technology platforms are designed to optimize the patient experience for subcutaneous drugs, especially for drugs that are difficult to formulate as ready-to-use, stable products in volumes compatible with well-established injection devices:
- Concentrating high-dose drugs so they can be self-administered at home rather than by an HCP in a clinic
- Creating stable, ready-to-use drugs rather than requiring reconstitution or resuspension
- Concentrating drugs to decrease injection volume
XeriSol®
Nonaqueous, stable liquid formulation technology enabling the delivery of peptides and other small molecules via subcutaneous or intramuscular injection – without the need for refrigeration or reconstitution. XeriSol has been integrated into GVOKE® and is being leveraged in other Xeris development programs, such as XP-8121.
XeriJect®
Nonaqueous subcutaneous injection platform enabling stable, high concentration biologics (>400 mg/mL). XeriJect® has been validated through successful formulation development and preclinical testing with multiple large and start-up biopharmaceutical partners.